Stay updated with breaking news from Agent Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ARCH Venture Partners-backed Orbital Therapeutics’ is researching next-generation RNA medicines that offer advantages over currently available therapies. The startup’s three areas of focus are vaccines, protein replacement, and immunomodulation.
Closed merger with Sesen Bio and commenced trading on Nasdaq under ticker symbol CARM Cash position as of the closing of the merger with Sesen Bio provides anticipated operating runway through... | April 4, 2023
/PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and...
Notably, Center City and suburban biotech and pharma companies started the new year off with millions invested ahead of clinical trials and development.
Troutman Pepper client Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company, recently announced the initial closing of its Series D financing of up to $37.7 million.